Suppr
超能文献

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).

作者信息

Catapano Alberico L, Graham Ian, De Backer Guy, Wiklund Olov, Chapman M John, Drexel Heinz, Hoes Arno W, Jennings Catriona S, Landmesser Ulf, Pedersen Terje R, Reiner Željko, Riccardi Gabriele, Taskinen Marja-Riita, Tokgozoglu Lale, Verschuren W M Monique, Vlachopoulos Charalambos, Wood David A, Zamorano Jose Luis

出版信息

Atherosclerosis. 2016 Oct;253:281-344. doi: 10.1016/j.atherosclerosis.2016.08.018. Epub 2016 Sep 1.

DOI:10.1016/j.atherosclerosis.2016.08.018

PMID:27594540

Abstract

摘要

相似文献

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).

Atherosclerosis. 2016 Oct;253:281-344. doi: 10.1016/j.atherosclerosis.2016.08.018. Epub 2016 Sep 1.

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Atherosclerosis. 2011 Jul;217 Suppl 1:S1-44. doi: 10.1016/j.atherosclerosis.2011.06.012.

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272. Epub 2016 Aug 27.

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Atherosclerosis. 2011 Jul;217(1):3-46. doi: 10.1016/j.atherosclerosis.2011.06.028.

Eur Heart J. 2011 Jul;32(14):1769-818. doi: 10.1093/eurheartj/ehr158. Epub 2011 Jun 28.

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.

[ECS guidelines 2016 - dyslipidaemias].

Herz. 2016 Dec;41(8):671-676. doi: 10.1007/s00059-016-4505-6.

[Comments on the ESC/EAS guidelines for the management of dyslipidaemias 2011. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology].

Rev Esp Cardiol. 2011 Dec;64(12):1090-5. doi: 10.1016/j.recesp.2011.10.004.

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

Atherosclerosis. 2019 Nov;290:140-205. doi: 10.1016/j.atherosclerosis.2019.08.014. Epub 2019 Aug 31.

Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias.

Clin Investig Arterioscler. 2020 Sep-Oct;32(5):209-218. doi: 10.1016/j.arteri.2019.12.003. Epub 2020 Feb 6.

引用本文的文献

Efficacy and Safety of Moderate-Intensity Statin and Ezetimibe Combination Therapy Versus High-Intensity Statin Monotherapy in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

J Lipid Atheroscler. 2025 May;14(2):145-158. doi: 10.12997/jla.2025.14.2.145. Epub 2025 Feb 11.

Effects of Omega-3 Fatty Acids Intake on Lipid Metabolism and Plaque Volume in Patients With Coronary Heart Disease: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials.

Food Sci Nutr. 2025 Jun 2;13(6):e70372. doi: 10.1002/fsn3.70372. eCollection 2025 Jun.

Evolocumab Versus Statins and Placebo in Patients With Cardiovascular Disease and Comorbidities: A Systematic Review and Meta-Analysis.

Cureus. 2025 Apr 10;17(4):e82037. doi: 10.7759/cureus.82037. eCollection 2025 Apr.

Fiber in the Treatment of Dyslipidemia in Pediatric Patients.

Children (Basel). 2025 Mar 28;12(4):427. doi: 10.3390/children12040427.

Evaluation of the effectiveness and safety of preoperative drug elution balloon therapy in patients with elective tumor surgery and coronary heart disease: a retrospective clinical study : The best choice of PCI for patients with elective tumor surgery and CHD.

BMC Cardiovasc Disord. 2025 Mar 12;25(1):171. doi: 10.1186/s12872-025-04623-w.

The nonlinear relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol and the risk of diabetic kidney disease in patients with type 2 diabetes mellitus.

Front Med (Lausanne). 2025 Feb 19;12:1492483. doi: 10.3389/fmed.2025.1492483. eCollection 2025.

2024 Polish recommendations for the management of familial hypercholesterolemia in children and adolescents.

Arch Med Sci. 2024 Nov 22;20(6):1741-1753. doi: 10.5114/aoms/196329. eCollection 2024.

Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment.

Nat Rev Gastroenterol Hepatol. 2025 May;22(5):314-328. doi: 10.1038/s41575-025-01045-z. Epub 2025 Feb 17.

Genetic Insights Into Lipid Traits and Lipid-Modifying Drug Targets in Pregnancy Complications: A Two-Sample Mendelian Randomization Study.

Int J Womens Health. 2025 Jan 31;17:221-234. doi: 10.2147/IJWH.S496268. eCollection 2025.

Pemafibrate ameliorates renal injury through induction of FGF21 and ketone body production in male mice.

Physiol Rep. 2025 Feb;13(3):e70135. doi: 10.14814/phy2.70135.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。